Last updated on July 2020

Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)

Brief description of study

A multi-center evaluation of aldafermin in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis.

Detailed Study Description

The study will compare multiple doses of aldafermin against placebo in a compensated NASH cirrhosis population for 48 weeks of treatment.

Clinical Study Identifier: NCT04210245

Find a site near you

Start Over

NGM Clinical Study Site

Westmead, Australia
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.